Anlon Healthcare's IPO listed weakly on BSE and NSE after excellent subscription. On NSE, the shares listed at 92 rupees against an issue price of 91 rupees, while on BSE, they listed at 91 rupees. Retail investors showed the most interest, with an 8.95 times subscription. The company manufactures Pharma Intermediates and APIs.
Anlon Healthcare IPO Listing: Chemical manufacturing company Anlon Healthcare Limited listed on BSE and NSE on Wednesday, but experienced a weaker than expected debut. On NSE, shares opened at 92 rupees against an issue price of 91 rupees, a mere 1.10% premium, while on BSE, it listed at 91 rupees. The company's IPO opened on August 26 and received a tremendous response, particularly from retail investors who subscribed 8.95 times. Anlon Healthcare produces pharmaceutical intermediates and APIs and recorded a profit of 20.51 crore rupees on an income of 120 crore rupees in FY25.
Performance on Listing Day
Anlon Healthcare's share listed at 92 rupees on the National Stock Exchange (NSE) against an issue price of 91 rupees. This means it opened with only a 1.10% premium. On the Bombay Stock Exchange (BSE), it listed directly at 91 rupees with no premium. This outcome was surprising for investors who had bid in large numbers for this IPO.
Subscription Details
The company offered a total of 1.33 crore shares through this IPO. In comparison, applications were received for 2.24 crore shares from investors, indicating demand exceeding the offer. The most enthusiasm was seen among retail investors.
Applications for 1.19 crore shares were received against the 13.3 lakh shares reserved for retail investors. This figure represents approximately 8.95 times subscription, showing significant interest from small investors in this IPO.
Share of Qualified and Non-Institutional Investors
Good participation was also observed from Qualified Institutional Buyers (QIBs). This segment received a total subscription of 91%. Applications for 90.9 lakh shares were received against a demand for 99.8 lakh shares.
Meanwhile, the response from Non-Institutional Investors (NII) was slightly weaker. The company offered 20 lakh shares in this category, against which applications for only 14.2 lakh shares were received. This means this portion was only subscribed to 71%.
Company's Business Model and Products
Anlon Healthcare is a leading chemical manufacturing company. Its business involves the production of pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs). The company's products are used in tablets, capsules, syrups, personal care, and animal health products.
The growing demand in the pharma sector and the global need for medicines have provided this company with an opportunity for rapid growth.
Company's Revenue and Profit
The company's performance was b in the financial year 2024-25. During this period, Anlon Healthcare registered an income of 120 crore rupees and earned a profit of 20.51 crore rupees. These results indicate that the company is continuously expanding its business and strengthening its market position.
Investor Expectations and Listing Response
Given the response during the subscription period, investors expected good returns on listing. However, in reality, the stock's performance was below expectations. While a marginal premium was seen on NSE, there was no gain on BSE.
This implies that the listing of the company's shares surprised investors. However, market experts believe that considering the company's business model and consistently growing profits, it may hold good long-term potential.
